FilingSEC EDGAR8-K
Karyopharm Therapeutics to Delist from Nasdaq Following Bankruptcy Filing
· SEC accepted
StageBankruptcy proceedings
Filing content
Following its Chapter 11 bankruptcy filing, the company will be delisted from Nasdaq, with trading suspended on November 11, 2026, and expected to move to the OTC market.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…